Johannes Levin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/44294/publications.pdf

Version: 2024-02-01

223 papers	12,548 citations	36303 51 h-index	32842 100 g-index
271 all docs	271 docs citations	271 times ranked	14436 citing authors

#	Article	IF	Citations
1	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
2	Neurostimulation for Parkinson's Disease with Early Motor Complications. New England Journal of Medicine, 2013, 368, 610-622.	27.0	1,138
3	Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimerâ€™s disease. Nature Medicine, 2019, 25, 277-283.	30.7	610
4	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
5	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimerâ€™s disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
6	Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinsonâ€™s disease. Acta Neuropathologica, 2013, 125, 795-813.	7.7	327
7	Hough-CNN: Deep learning for segmentation of deep brain regions in MRI and ultrasound. Computer Vision and Image Understanding, 2017, 164, 92-102.	4.7	282
8	Early increase of CSF sTREM2 in Alzheimerâ€™s disease is associated with tau related-neurodegeneration but not with amyloid-Î² pathology. Molecular Neurodegeneration, 2019, 14, 1.	10.8	253
9	Inhibition and disaggregation of Î±-synuclein oligomers by natural polyphenolic compounds. FEBS Letters, 2011, 585, 1113-1120.	2.8	240
10	Early changes in CSF sTREM2 in dominantly inherited Alzheimerâ€™s disease occur after amyloid deposition and neuronal injury. Science Translational Medicine, 2016, 8, 369ra178.	12.4	211
11	Single Particle Characterization of Iron-induced Pore-forming Î±-Synuclein Oligomers. Journal of Biological Chemistry, 2008, 283, 10992-11003.	3.4	204
12	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.1	193
13	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
14	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathologica, 2015, 130, 537-555.	7.7	157
15	Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408.	9.0	145
16	Four-repeat tauopathies. Progress in Neurobiology, 2019, 180, 101644.	5.7	141
17	First symptom in sporadic Creutzfeldt-Jakob disease. Neurology, 2006, 66, 286-287.	1.1	140
18	Extracellular vesicle sorting of Î±-Synuclein is regulated by sumoylation. Acta Neuropathologica, 2015, 129, 695-713.	7.7	136

#	Article	IF	Citations
19	The Differential Diagnosis and Treatment of Atypical Parkinsonism. Deutsches Ärzteblatt International, 2016, 113, 61-9.	0.9	135
20	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
21	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
22	slan-defined subsets of CD16-positive monocytes: impact of granulomatous inflammation and M-CSF receptor mutation. Blood, 2015, 126, 2601-2610.	1.4	116
23	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimerâ€™s disease. Brain, 2018, 141, 3065-3080.	7.6	116
24	Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Science Translational Medicine, 2021, 13, eabe5640.	12.4	108
25	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	1.9	106
26	Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurology, The, 2018, 17, 223-231.	10.2	105
27	The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathologica, 2014, 127, 779-780.	7.7	103
28	A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. Advances in Urology, 2012, 2012, 1-10.	1.3	101
29	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
30	Effect of metal ions on de novo aggregation of full-length prion protein. Biochemical and Biophysical Research Communications, 2004, 320, 1240-1246.	2.1	92
31	Polyâ€<scp>GP</scp> in cerebrospinal fluid links C9orf72â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp>/<scp>FTD</scp>. EMBO Molecular Medicine, 2017, 9, 859-868.	6.9	90
32	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	1.9	89
33	Opposite microglial activation stages upon loss of <scp>PGRN</scp> or <scp>TREM</scp> 2 result in reduced cerebral glucose metabolism. EMBO Molecular Medicine, 2019, 11, .	6.9	87
34	Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1186-1200.	7.6	83
35	Increased Î±-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Experimental Neurology, 2009, 215, 201-208.	4.1	80
36	Preferential degradation of cognitive networks differentiates Alzheimerâ€™s disease from ageing. Brain, 2018, 141, 1486-1500.	7.6	79

#	Article	IF	Citations
37	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2019, 18, 724-735.	10.2	79
38	Single-Channel Electrophysiology Reveals a Distinct and Uniform Pore Complex Formed by Î±-Synuclein Oligomers in Lipid Membranes. PLoS ONE, 2012, 7, e42545.	2.5	75
39	Multiple system atrophy. International Review of Neurobiology, 2019, 149, 137-192.	2.0	74
40	A critique of the second consensus criteria for multiple system atrophy. Movement Disorders, 2019, 34, 975-984.	3.9	73
41	Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 655-665.	0.8	72
42	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	10.2	72
43	BDNFVal66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimerâ€™s disease. Brain, 2016, 139, 2766-2777.	7.6	70
44	Segregation of functional networks is associated with cognitive resilience in Alzheimerâ€™s disease. Brain, 2021, 144, 2176-2185.	7.6	66
45	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	6.9	64
46	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 703-713.	3.7	63
47	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimerâ€™s disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
48	Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with Î±-synuclein at the single molecule level. Molecular Neurodegeneration, 2012, 7, 35.	10.8	60
49	Objective measurement of muscle rigidity in parkinsonian patients treated with subthalamic stimulation. Movement Disorders, 2009, 24, 57-63.	3.9	58
50	Generation of Ferric Iron Links Oxidative Stress to Î±-Synuclein Oligomer Formation. Journal of Parkinson's Disease, 2011, 1, 205-216.	2.8	58
51	Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathologica, 2015, 130, 619-631.	7.7	58
52	[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. Frontiers in Aging Neuroscience, 2017, 9, 440.	3.4	58
53	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	1.9	55
54	Converse modulation of toxic Î±-synuclein oligomers in living cells by Nâ€²-benzylidene-benzohydrazide derivates and ferric iron. Biochemical and Biophysical Research Communications, 2010, 391, 461-466.	2.1	52

#	Article	IF	Citations
55	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.1	52
56	The Value of the Dopamine D_{2/3} Receptor Ligand ¹⁸F-Desmethoxyfallypride for the Differentiation of Idiopathic and Nonidiopathic Parkinsonian Syndromes. Journal of Nuclear Medicine, 2010, 51, 581-587.	5.0	51
57	Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1427-1437.	0.8	51
58	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's diseaseâ€informed machineâ€learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.8	47
59	Cortical [<scp>¹⁸F</scp>]<scp>PI</scp>â€2620 Binding Differentiates Corticobasal Syndrome Subtypes. Movement Disorders, 2021, 36, 2104-2115.	3.9	46
60	Single particle analysis of manganese-induced prion protein aggregates. Biochemical and Biophysical Research Communications, 2005, 329, 1200-1207.	2.1	45
61	Different Effects of Î±-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements. ACS Chemical Neuroscience, 2019, 10, 1649-1659.	3.5	44
62	Accelerated functional brain aging in pre-clinical familial Alzheimerâ€™s disease. Nature Communications, 2021, 12, 5346.	12.8	43
63	Decreased body mass index in the preclinical stage of autosomal dominant Alzheimerâ€™s disease. Scientific Reports, 2017, 7, 1225.	3.3	42
64	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. Movement Disorders, 2020, 35, 595-605.	3.9	42
65	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
66	Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. Experimental Neurology, 2012, 237, 470-476.	4.1	41
67	Elevated Levels of Methylmalonate and Homocysteine in Parkinsonâ€™s Disease, Progressive Supranuclear Palsy and Amyotrophic Lateral Sclerosis. Dementia and Geriatric Cognitive Disorders, 2010, 29, 553-559.	1.5	40
68	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€“ An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	3.4	40
69	Two Different Binding Modes of Î±-Synuclein to Lipid Vesicles Depending on its Aggregation State. Biophysical Journal, 2012, 102, 1646-1655.	0.5	39
70	Psychosis in Parkinsonâ€™s disease: identification, prevention and treatment. Journal of Neural Transmission, 2016, 123, 45-50.	2.8	39
71	Seizures in Alzheimerâ€™s disease are highly recurrent and associated with a poor disease course. Journal of Neurology, 2020, 267, 2941-2948.	3.6	38
72	Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. EMBO Journal, 2022, 41, e109108.	7.8	38

#	Article	IF	Citations
73	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
74	In Vivo Assessment of Neuroinflammation in <scp>4â€Repeat</scp> Tauopathies. Movement Disorders, 2021, 36, 883-894.	3.9	37
75	MR imaging differentiation of Fe2+ and Fe3+ based on relaxation and magnetic susceptibility properties. Neuroradiology, 2017, 59, 403-409.	2.2	36
76	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimerâ€™s disease. Brain, 2019, 142, 1429-1440.	7.6	36
77	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2911-2922.	6.4	36
78	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
79	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. Alzheimer's and Dementia, 2020, 16, 1504-1514.	0.8	35
80	Variant-dependent heterogeneity in amyloid Î² burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	10.2	34
81	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
82	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	4.2	33
83	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. Journal of Neural Transmission, 2016, 123, 439-445.	2.8	32
84	Multivariate Analysis of 18F-DMFP PET Data to Assist the Diagnosis of Parkinsonism. Frontiers in Neuroinformatics, 2017, 11, 23.	2.5	32
85	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. Neurobiology of Disease, 2020, 142, 104960.	4.4	31
86	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	3.9	31
87	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.8	31
88	PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes. Frontiers in Aging Neuroscience, 2019, 11, 249.	3.4	30
89	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 776-785.	1.3	30
90	Binding characteristics of [¹⁸F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2957-2972.	4.3	30

#	Article	IF	Citations
91	Characterizing the Clinical Features and Atrophy Patterns of MAPT -Related Frontotemporal Dementia With Disease Progression Modeling. Neurology, 2021, 97, e941-e952.	1.1	29
92	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurology, The, 2021, 20, 605-614.	10.2	29
93	Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimerâ€™s disease tau. Alzheimer's Research and Therapy, 2019, 11, 67.	6.2	28
94	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Translational Psychiatry, 2019, 9, 54.	4.8	28
95	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
96	Alpha frequency modulation in the human basal ganglia is dependent on motor task. European Journal of Neuroscience, 2011, 33, 960-967.	2.6	27
97	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
98	Seizures as an early symptom of autosomal dominant Alzheimer's disease. Neurobiology of Aging, 2019, 76, 18-23.	3.1	27
99	Biphasic cortical macroâ€•and microstructural changes in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 618-628.	0.8	27
100	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
101	Bundle-specific associations between white matter microstructure and Aî² and tau pathology in preclinical Alzheimerâ€™s disease. ELife, 2021, 10, .	6.0	26
102	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2021, 20, 615-626.	10.2	26
103	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
104	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine, 2022, 80, 104021.	6.1	26
105	Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease. Annals of Neurology, 2018, 84, 424-435.	5.3	25
106	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	1.9	25
107	Modelling Ser129 Phosphorylation Inhibits Membrane Binding of Pore-Forming Alpha-Synuclein Oligomers. PLoS ONE, 2014, 9, e98906.	2.5	24
108	COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. Journal of Clinical Medicine, 2021, 10, 5125.	2.4	24

#	Article	IF	Citations
109	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
110	Distinguishing Parkinson's disease from atypical parkinsonian syndromes using PET data and a computer system based on support vector machines and Bayesian networks. Frontiers in Computational Neuroscience, 2015, 9, 137.	2.1	23
111	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy. Frontiers in Neuroscience, 2016, 10, 99.	2.8	23
112	Cerebral Glucose Metabolism and Dopaminergic Function in Patients with Corticobasal Syndrome. Journal of Neuroimaging, 2017, 27, 255-261.	2.0	23
113	IgLON5: A case with predominant cerebellar tau deposits and leptomeningeal inflammation. Neurology, 2018, 91, 180-182.	1.1	23
114	Education modulates brain maintenance in presymptomatic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1124-1130.	1.9	23
115	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	5.9	23
116	Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimer's and Dementia, 2021, 17, 1595-1609.	0.8	22
117	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3872-3885.	6.4	22
118	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. Frontiers in Neurology, 2018, 9, 483.	2.4	21
119	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
120	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	3.3	20
121	Autosomal dominant and sporadic late onset Alzheimer's disease share a commonin vivopathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
122	Progressive supranuclear palsy and multiple system atrophy: clinicopathological concepts and therapeutic challenges. Current Opinion in Neurology, 2018, 31, 448-454.	3.6	19
123	Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning. Journal of Neuroinflammation, 2020, 17, 208.	7.2	19
124	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19
125	Symptomatic therapy of multiple system atrophy. Autonomic Neuroscience: Basic and Clinical, 2018, 211, 26-30.	2.8	18
126	Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson's disease: A multi-modal atlas study with transcranial ultrasound and MRI. NeuroImage: Clinical, 2020, 26, 102185.	2.7	18

#	Article	IF	Citations
127	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	1.2	18
128	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	1.7	18
129	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	2.4	17
130	Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning. Information Fusion, 2020, 58, 153-167.	19.1	17
131	Drip and ship for mechanical thrombectomy within the Neurovascular Network of Southwest Bavaria. Neurology, 2020, 94, e453-e463.	1.1	17
132	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
133	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
134	Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2239-2248.	6.4	15
135	The applause sign in frontotemporal lobar degeneration and related conditions. Journal of Neurology, 2019, 266, 330-338.	3.6	15
136	Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	9.0	15
137	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. NeuroImage: Clinical, 2019, 24, 101949.	2.7	14
138	Divergent Molecular Effects of Desmin Mutations on Protein Assembly in Myofibrillar Myopathy. Journal of Neuropathology and Experimental Neurology, 2010, 69, 415-424.	1.7	13
139	Pontine and extrapontine myolinolysis associated with hypernatraemia. Clinical Neurology and Neurosurgery, 2012, 114, 1290-1291.	1.4	13
140	Onset latency of segmental dystonia after deep brain stimulation cessation: A randomized, doubleâ€blind crossover trial. Movement Disorders, 2014, 29, 944-949.	3.9	13
141	Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN). Alzheimer's and Dementia, 2020, 16, 219-228.	0.8	13
142	Dual-Phase Î²-Amyloid PET Captures Neuronal Injury and Amyloidosis in Corticobasal Syndrome. Frontiers in Aging Neuroscience, 2021, 13, 661284.	3.4	13
143	Cognitive reserve hypothesis in frontotemporal dementia: A FDG-PET study. NeuroImage: Clinical, 2021, 29, 102535.	2.7	13
144	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	3.9	13

#	Article	IF	Citations
145	Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 2687-2698.	0.8	13
146	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	1.9	12
147	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
148	Modeling autosomal dominant Alzheimer's disease with machine learning. Alzheimer's and Dementia, 2021, 17, 1005-1016.	0.8	12
149	Hypometabolism in Brain of Cognitively Normal Patients with Depressive Symptoms is Accompanied by Atrophy-Related Partial Volume Effects. Current Alzheimer Research, 2016, 13, 475-486.	1.4	12
150	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. Movement Disorders, 2017, 32, 1356-1364.	3.9	11
151	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimerâ€™s disease. Brain Communications, 2020, 2, fcaa102.	3.3	11
152	Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. PLoS ONE, 2020, 15, e0231495.	2.5	11
153	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
154	First symptom guides diagnosis and prognosis in neurodegenerative diseasesâ€”a retrospective study of autopsy proven cases. European Journal of Neurology, 2021, 28, 1801-1811.	3.3	11
155	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. Life, 2021, 11, 484.	2.4	11
156	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for in vitro Assessment of Progressive Supranuclear Palsy Tau Pathology With [18F]PI-2620. Frontiers in Neurology, 2021, 12, 684523.	2.4	11
157	Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice. PLoS ONE, 2017, 12, e0188989.	2.5	11
158	Diffuse leukoencephalopathy with spheroids: Biopsy findings and a novel mutation. Clinical Neurology and Neurosurgery, 2014, 122, 113-115.	1.4	10
159	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	1.9	10
160	Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12184.	2.4	10
161	The association of aphasia and right-sided motor impairment in corticobasal syndrome. Journal of Neurology, 2015, 262, 2241-2246.	3.6	9
162	Postinfectious Opsoclonusâ€Myoclonus Syndrome in a 41â€Yearâ€Old Patientâ€”Visualizing Hyperactivation in Deep Cerebellar Nuclei by Cerebral [¹⁸F]â€FDGâ€PET. Journal of Neuroimaging, 2015, 25, 683-685.	2.0	9

#	Article	IF	Citations
163	Current Treatment of Multiple System Atrophy. Current Treatment Options in Neurology, 2016, 18, 51.	1.8	9
164	Identification of a rare presenilin 1 single amino acid deletion mutation (F175del) with unusual amyloid-Î² processing effects. Neurobiology of Aging, 2019, 84, 241.e5-241.e11.	3.1	9
165	Relationships between bigâ€five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12038.	2.4	9
166	Inter-hospital transfer for mechanical thrombectomy within the supraregional stroke network NEVAS. Journal of Neurology, 2021, 268, 623-631.	3.6	9
167	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimerâ€™s Disease. Journal of Clinical Medicine, 2021, 10, 4582.	2.4	9
168	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
169	Serum <scp>Betaâ€Synuclein</scp> Is Higher in Down Syndrome and Precedes Rise of <scp>pTau181</scp>. Annals of Neurology, 2022, 92, 6-10.	5.3	9
170	Multicenter 18F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimerâ€™s Disease. Biomolecules, 2022, 12, 458.	4.0	9
171	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	2.5	9
172	Analysis of 18F-DMFP PET data using multikernel classification in order to assist the diagnosis of Parkinsonism. , 2015, , .		8
173	Perfusion-Phase [18F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration. Journal of Alzheimer's Disease Reports, 2017, 1, 109-113.	2.2	8
174	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	6.2	8
175	Increased cerebral microbleeds and cortical superficial siderosis in pediatric patients with Down syndrome. European Journal of Paediatric Neurology, 2019, 23, 158-164.	1.6	8
176	Binding of Metal-Ion-Induced Tau Oligomers to Lipid Surfaces Is Enhanced by GSK-3Î²-Mediated Phosphorylation. ACS Chemical Neuroscience, 2020, 11, 880-887.	3.5	8
177	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	2.7	8
178	COVID-19 Vaccination of Individuals with Down Syndromeâ€”Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. Vaccines, 2022, 10, 530.	4.4	8
179	¹⁸F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy. Journal of Nuclear Medicine, 2022, , jnumed.121.262854.	5.0	8
180	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	1.9	7

#	Article	IF	Citations
181	Dataâ€driven staging of genetic frontotemporal dementia using multiâ€modal <scp>MRI</scp>. Human Brain Mapping, 2022, 43, 1821-1835.	3.6	7
182	CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiology of Disease, 2022, 168, 105714.	4.4	7
183	Programming parameters of subthalamic deep brain stimulators in Parkinson's disease from a controlled trial. Parkinsonism and Related Disorders, 2019, 65, 217-223.	2.2	6
184	Seizure prevalence in neurodegenerative diseasesâ€"a study of autopsy proven cases. European Journal of Neurology, 2022, 29, 12-18.	3.3	6
185	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.1	5
186	Essential tremor leading to toxic liver damage successfully treated with deep brain stimulation. Acta Neurochirurgica, 2009, 151, 1305-1307.	1.7	4
187	Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 2097-2099.	3.6	4
188	Intracellular formation of Î±-synuclein oligomers and the effect of heat shock protein 70 characterized by confocal single particle spectroscopy. Biochemical and Biophysical Research Communications, 2016, 477, 76-82.	2.1	4
189	Pattern and degree of individual brain atrophy predicts dementia onset in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12197.	2.4	4
190	Low-degree trisomy 21 mosaicism promotes early-onset Alzheimer disease. Neurobiology of Aging, 2021, 103, 147.e1-147.e5.	3.1	4
191	Different rates of cognitive decline in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 1754-1764.	0.8	4
192	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	6.2	4
193	Applied multimodal diagnostics in a case of presenile dementia. BMC Neurology, 2016, 16, 131.	1.8	3
194	Longitudinal correlation between neurofilament light chain and UMSARS in Multiple System Atrophy. Clinical Neurology and Neurosurgery, 2020, 195, 105924.	1.4	3
195	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	3.1	3
196	ICâ€Pâ€161: 18Fâ€PI2620 TAUâ€PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTIâ€CENTER EVALUATION. Alzheimer's and Dementia, 2019, 15, P128.	0.8	3
197	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	2.6	3
198	Effects of Low-Intensity Vestibular Noise Stimulation on Postural Instability in Patients with Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 1611-1618.	2.8	3

#	Article	IF	Citations
199	Multiple System Atrophy. , 2017, , 183-192.		2
200	[P4â€“189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1337.	0.8	2
201	Parkinsonism in genetic and sporadic Alzheimer's disease. International Review of Neurobiology, 2019, 149, 237-247.	2.0	2
202	A baseline study for detection of Parkinson's disease with 3D-transcranial sonography and uni-lateral reconstruction. Journal of the Neurological Sciences, 2019, 397, 16-21.	0.6	2
203	Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 611595.	3.4	2
204	Impact of Partial Volume Correction on [18F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome. Brain Sciences, 2022, 12, 204.	2.3	2
205	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
206	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
207	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.8	2
208	Three cases of isolated resting tremor of the lower limbs. Basal Ganglia, 2018, 11, 1-3.	0.3	1
209	P4â€094: OCCIPITAL TO GLOBAL PIB UPTAKE IS ASSOCIATED WITH THE PRESENCE OF MICROHEMORRHAGES AND MUTATIONS ASSOCIATED WITH CEREBRAL AMYLOID ANGIOPATHY IN THE DOMINANTLY INHERITED ALZHEIMER'S NETWORK. Alzheimer's and Dementia, 2018, 14, P1472.	0.8	1
210	ICâ€Pâ€090: CROSSâ€VALIDATED BIOMARKERâ€BASED PREDICTION OF 4â€YEAR RATE OF COGNITIVE DECLINE IN NONâ€DEMENTED SUBJECTS AT RISK OF AD. Alzheimer's and Dementia, 2018, 14, P75.	0.8	1
211	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
212	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	3.6	1
213	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
214	Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.8	1
215	G.P.123 Identification of molecular effects of FHL1 mutations on protein assembly in reducing body myopathy. Neuromuscular Disorders, 2012, 22, 903.	0.6	0
216	Oligoclonal bands in hereditary diffuse leukencephalopathy with spheroids. European Journal of Neurology, 2015, 22, e48-e48.	3.3	0

#	Article	IF	Citations
217	P1â€497: CLINICAL CORRELATES OF LEWY BODY PATHOLOGY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE. Alzheimer's and Dementia, 2018, 14, P520.	0.8	0
218	ICâ€Pâ€067: THE BDNFVAL66MET SNP IS RELATED TO HIPPOCAMPAL CONNECTIVITY AND COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P60.	0.8	0
219	P3â€426: CROSSâ€VALIDATED BIOMARKERâ€BASED PREDICTION OF 4â€YEAR RATE OF COGNITIVE DECLINE IN NONâ€DEMENTED SUBJECTS AT RISK OF AD. Alzheimer's and Dementia, 2018, 14, P1273.	0.8	0
220	O4â€04â€05: FIBERâ€TRACTâ€“SPECIFIC DECLINE IN WHITEâ€MATTER INTEGRITY DURING THE ADULT LIFESPAN AND PRECLINICAL ALZHEIMER'S DISEASE: RESULTS FROM THE DALLAS LIFESPAN BRAIN STUDY AND DIAN. Alzheimer's and Dementia, 2018, 14, P1410.	0.8	0
221	CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease. SSRN Electronic Journal, 0, , .	0.4	0
222	Associations between sex, body mass index, and the individual microglial response in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
223	A dataâ€driven disease progression model of fluid biomarkers in genetic FTD. Alzheimer's and Dementia, 2021, 17, .	0.8	0